pcn poster

Posters

Efficacy (NNT) and Tolerability (NNH) of Cariprazine in Bipolar Disorder

Background: Cariprazine is approved to treat manic, mixed, and depressive symptoms of bipolar I disorder. This analysis describes the efficacy and tolerability of cariprazine in bipolar I...

Willie Earley , MD;

Mehul Patel , MD, PharmD;

Mauricio Tohen , MD, DrPH, MBA;

Leslie Citrome , MD;

11/22/2019

Solriamfetol Treatment of Excessive Daytime Sleepiness in Participants With Narcolepsy or Obstructive Sleep Apnea With a History of Depression

Background: Depression is commonly comorbid with narcolepsy and obstructive sleep apnea (OSA). Solriamfetol (SunosiTM), a dopamine/norepinephrine reuptake inhibitor, has been approved in ...

Lawrence Lee , PhD;

Russell 1022962 , PhD;

Atul Malhotra , MD;

Paula Schweitzer , MD, PhD;

Kimberly Babson , PhD;

Shay Bujanover , MD;

Kingman Strohl , MD;

Ruth Benca , MD, PhD;

11/22/2019

Withdrawal Symptom Assessment in an Esketamine Safety Study in Patients With Treatment-Resistant Depression in SUSTAIN-2 (NCT02497287)

We assessed potential withdrawal symptoms in patients with treatment-resistant depression (TRD) after long-term, intermittent use of intranasal esketamine (ESK). Patients received ESK 2X/...

Allitia DiBernardo , MD;

Ewa Wajs , MD, PhD;

Andrew Krystal , MD;

Lynn Yieh , PhD;

Ella Daly , MB, BCh, BAO;

Leah Aluisio , PhD;

Wayne Drevets , MD;

Yun Wu , PhD;

Jaskaran Singh , MD;

Peter Zannikos , PhD;

Jagadish Gogate , PhD;

Valerie Curran , PhD;

Guang Chen , MD, PhD;

11/22/2019

Results From a 12-Month Open-Label Safety Study of Lumateperone (ITI-007) in Patients With Stable Symptoms of Schizophrenia

Introduction: Lumateperone (ITI-007) is in development for the treatment of schizophrenia and bipolar depression. Lumateperone has a unique mechanism of action that simultaneously modulat...

Jelena Saillard , MS, MBA;

Christoph U. Correll , MD;

Suresh Durgam , MD;

Robert Davis , PhD;

Andrew Satlin , MD;

Sharon Mates , PhD;

Kimberly Vanover , PhD;

11/22/2019

Trauma-Informed Care in the Middle East

Introduction: The problem of increased level and severity of stress as a result of regional and international conflicts is not paralleled by an adequate level of knowledge and preparednes...

11/22/2019

CLARITY: A Phase 2 Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder

This study examined pimavanserin (PIM), a 5-HT2A receptor inverse agonist/antagonist, as a potential adjunct to SSRIs or SNRIs for major depressive disorder (MDD). Adult female and male p...

Michael Thase , MD;

Richard Shelton , MD;

Keith Liu , PhD;

Susan Legacy , MD;

Bryan Dirks , MD, MSc, MBA;

Marlene Freeman , MD;

George Papakostas , MD;

Maurizio Fava , MD, PhD;

Madhukar Trivedi , MD;

Srdjan Stankovic , MD, MSPH;

11/22/2019

Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Adult Patients at Imminent Risk for Suicide: ASPIRE-1, a Phase 3 Randomized Study

Introduction: ASPIRE-1 is one of two global phase-3 studies in the registration program to evaluate efficacy and safety of esketamine nasal spray (ESK) vs placebo, with comprehensive stan...

Dong Jing Fu , MD, PhD;

Carla M. Canuso , MD;

Dawn F. Ionescu , MD;

Xiang Li , PhD;

Rosanne Lane , MD, MSc, MS;

Pilar Lim , MD, PhD;

David Hough , MD;

Husseini Manji , MD;

Wayne Drevets , MD;

11/22/2019

Efficacy of Adjunctive Brexpiprazole in Major Depressive Disorder: A Pooled Response Quartile Analysis

Background: We assessed varying levels of response to brexpiprazole adjunctive to standard antidepressant therapy (ADT).

Catherine Weiss , PhD;

Stine Rasmussen Meehan , PhD;

Mary Hobart , PhD;

Dalei Chen , PhD;

11/22/2019

Older Adults` Mental Health Issues in Palliative Care on the Border (Rio Grande Valley): Cultural, Access and Immigration Status Challenge

The Rio Grande Valley (RGV) comprises the longest continuous area of population centers along the U.S.-Mexico border. Large cities (Nuevo Laredo, Reynosa, Matamoros) are connected by mult...

Andrew Dentino , MD;

11/22/2019

Journey of the Veteran Health Administration Population With Recent Schizophrenia Diagnosis: A Real-World Analysis of Treatment Patterns and Healthcare Burden

Background: Schizophrenia is a chronic mental disorder that affects ~0.3-0.7% of the population worldwide and poses a significant economic and societal burden. Objectives: To describe tr...

Charmi Patel , BS , RN, BSN, MPH;

Ahong Huang , BS , MS;

Li Wang , MS, MBA, PhD, MA;

Yoshita Paliwal , PhD;

Kruti Joshi , MPH, MD;

11/22/2019

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Rapid Refresh

Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics

04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...

Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...

Andrew Penn, MS, PMHNP, and...

04/11/2024

Psych Congress NP Institute

Rapid Refresh

Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder

04/10/2024

Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...

Amber Hoberg, PMHNP-BC,...

04/10/2024

Psych Congress NP Institute

Clinical Pearls

Tolerability Testing in Long-Acting Injectable Prescriptions

04/03/2024

Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.

Posters

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Sign Up

Specialties

Events

Year Round Education

HMP Global Products